Korean J Helicobacter Up Gastrointest Res.  2012 Mar;12(1):34-37. 10.7704/kjhugr.2012.12.1.34.

The Effect of Co-Administration of Rebamipide on the Expression of Serum Gastrin in Long-term Proton Pump Inhibitor Users: A Prospective Pilot Study

• Im EJ
• Kim BW
• Kim JS
• Lee HM
• Kim JI
• Kang BK
• Ji JS
• Lee BI
• Choi H

• KMID: 2305177
• DOI: http://doi.org/10.7704/kjhugr.2012.12.1.34

Abstract

BACKGROUND/AIMS
In one animal study, co-administration of rebamipide with proton pump inhibitors (PPIs) could suppress hypergastrinemia but there have been no such reports on humans. The aim of this study was to evaluate whether rebamipide could prevent hypergastrinemia in long-term PPI users.
MATERIALS AND METHODS
Patients who were diagnosed with reflux esophagitis endoscopically were enrolled in this study. In the control group, lansoprazole 30 mg was administered for 8 weeks and in the rebamipide group, lansoprazole 30 mg with rebamipide 300 mg was administered for 8 weeks. Serum gastrin level was checked before and after administration of the drugs.
RESULTS
Thirty patients were enrolled in this study. The control group included 17 patients and the rebamipide group included 13 patients. The gastrin level was elevated in the control group (28.4 pg/mL) compared to the rebamipide group (38.5 pg/mL). However, the gastrin level was decreased in 3 patients in the rebamipide group (23.1%) compared to 2 patients in the control group (11.8%).
CONCLUSIONS
Not all patients who are taking PPIs develop hypergastrinemia. Co-administration of rebamipide with PPI does not affect the serum gastrin level.

Keyword

Gastrins; Proton pump inhibitors; Rebamipide

MeSH Terms

2-Pyridinylmethylsulfinylbenzimidazoles
Alanine
Animals
Esophagitis, Peptic
Gastrins
Humans
Pilot Projects
Prospective Studies
Proton Pump Inhibitors
Proton Pumps
Protons
Quinolones
2-Pyridinylmethylsulfinylbenzimidazoles
Alanine
Gastrins
Proton Pump Inhibitors
Proton Pumps
Protons
Quinolones